ResMed Forecast, price target & analysts
ResMed Target price 2025 - Analyst rating & recommendation
ResMed Classifications & Recommendation:
ResMed Price Target
| Target Price | $306.00 |
| Price | $255.04 |
| Potential |
19.98%
register free of charge
|
| Number of Estimates | 17 |
|
17 Analysts have issued a price target ResMed 2026 .
The average ResMed target price is $306.00.
This is
19.98%
register free of charge
$346.50
35.86%
register free of charge
$217.15
14.86%
register free of charge
|
|
| A rating was issued by 25 analysts: 16 Analysts recommend ResMed to buy, 8 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the ResMed stock has an average upside potential 2026 of
19.98%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2030
| Jun '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion $ | 5.15 | 5.65 |
| 9.84% | 9.81% | |
| EBITDA Margin | 33.64% | 38.33% |
| 10.17% | 13.95% | |
| Net Margin | 27.22% | 28.34% |
| 24.91% | 4.12% |
24 Analysts have issued a sales forecast ResMed 2026 . The average ResMed sales estimate is
This results in the following potential growth metrics:
17 Analysts have issued an ResMed EBITDA forecast 2026. The average ResMed EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
22 ResMed Analysts have issued a net profit forecast 2026. The average ResMed net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2030
| Jun '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 9.51 | 10.97 |
| 37.43% | 15.35% | |
| P/E | 23.24 | |
| EV/Sales | 6.46 |
22 Analysts have issued a ResMed forecast for earnings per share. The average ResMed EPS is
This results in the following potential growth metrics and future valuations:
Current ResMed Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Baird |
Locked
➜
Locked
|
Locked | Nov 03 2025 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Oct 31 2025 |
| Keybanc |
Locked
➜
Locked
|
Locked | Oct 31 2025 |
| Mizuho |
Locked
➜
Locked
|
Locked | Oct 31 2025 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Oct 21 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Oct 13 2025 |
| Citigroup |
Locked
➜
Locked
|
Locked | Sep 18 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Baird:
Locked
➜
Locked
|
Nov 03 2025 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Oct 31 2025 |
|
Locked
Keybanc:
Locked
➜
Locked
|
Oct 31 2025 |
|
Locked
Mizuho:
Locked
➜
Locked
|
Oct 31 2025 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Oct 21 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Oct 13 2025 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Sep 18 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
